Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 3,088 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,088 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $93,967.84. Following the completion of the transaction, the chief financial officer now directly owns 129,211 shares in the company, valued at approximately $3,931,890.73. This represents a 2.33 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Trading Down 2.5 %

NASDAQ:APLS opened at $30.00 on Friday. The company has a market cap of $3.73 billion, a PE ratio of -14.78 and a beta of 0.94. The business’s 50 day moving average is $32.08 and its two-hundred day moving average is $33.15. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the business earned ($1.17) earnings per share. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC raised its stake in Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after acquiring an additional 939,289 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Apellis Pharmaceuticals by 12.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,376 shares of the company’s stock valued at $842,000 after purchasing an additional 2,956 shares during the last quarter. KBC Group NV grew its holdings in shares of Apellis Pharmaceuticals by 3,862.3% during the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock valued at $3,328,000 after purchasing an additional 101,655 shares during the last quarter. Merit Financial Group LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth approximately $254,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 135.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock worth $949,000 after purchasing an additional 17,115 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on APLS shares. Piper Sandler dropped their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price on the stock. Mizuho lowered their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a report on Tuesday, December 17th. Finally, Needham & Company LLC lowered their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).